ArticleInternational journal of molecular sciences2026
Effect of the JAK Inhibitor Baricitinib on Cytokine Production and Bone Properties in a Mouse Model of Accelerated Aging.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Age-related osteoporosis is characterized by progressive loss of bone mass and deterioration of bone microarchitecture, leading to enhanced skeletal fragility. Cytokines regulate bone remodeling through distinct signaling pathways. Baricitinib, a selective JAK1/2 inhibitor effective in inflammatory disorders such as rheumatoid arthritis, suppresses cytokine signaling, but its role in age-related osteoporosis remains insufficiently defined. In our study a total of 60 eight-month-old female SAMP8 mice were randomized to receive baricitinib (10 mg/kg) or vehicle twice daily by oral gavage for six weeks. Bone outcomes were evaluated by high-resolution micro-computed tomography (µCT) and static histomorphometry. Intracellular cytokine production by splenocytes was determined via flow cytometry. We found that baricitinib substantially reduced T-cell cytokine production, decreasing IL-6, IL-17, IFN-γ, and IL-21 in CD4
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.